- Health Canada has approved Cysklar (cysteamine ophthalmic solution), developed by Leadiant Biosciences, for treating corneal cystine crystal accumulation in patients with cystinosis
- Cystinosis is a rare, multi-system genetic disorder causing cystine crystal buildup across organs, including the eyes, often leading to vision complications
- Cysklar is a topical ophthalmic solution designed as an easy-to-use treatment option for managing corneal crystals in affected patients
- The approval marks a key milestone for the cystinosis community in Canada, with Leadiant planning to provide further updates on product availability
Takeaways:
Cysklar gives Canada’s small cystinosis community a dedicated, easy‑to‑use cysteamine eye‑drop option for corneal crystals, strengthening Leadiant’s rare‑disease ophthalmology footprint while addressing a clear unmet need in vision preservation.
Source: Businesswire